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Mammography and MRI for screening women who underwent chest radiation therapy (lymphoma 
survivors). Recommendations for surveillance from the Italian College of Breast Radiologists by SIRM 
 
 
Abstract 
Women who underwent chest radiation therapy (CRT) during pediatric/young-adult age (typically 
lymphoma survivors) have an increased breast cancer (BC) risk, in particular for high doses. The cumulative 
incidence from 40 to 45 years of age is 13-20%, similar to that of BRCA mutation carriers for whom 
contrast-enhanced magnetic resonance imaging (MRI) is recommended. However, in women who 
underwent CRT, MRI sensitivity is lower (63-80%) and that of mammography is higher (67-70%) than those 
observed in women with hereditary predisposition, due to a higher incidence of ductal carcinoma in situ 
with microcalcifications and low neoangiogenesis. A sensitivity close to 95% can be obtained only using 
mammography as an adjunct to MRI. Considering the available evidence, women who underwent CRT 
before 30 receiving a cumulative dose ≥ 10 Gy should be invited after 25 (or, at least, 8 years after CRT) to 
attend the following program: 1. Interview about individual risk profile and potential of breast imaging; 2. 
Annual MRI using the same protocol recommended for women with hereditary predisposition; 3. Annual 
bilateral 2-view full-field digital mammography or digital breast tomosynthesis (DBT) with synthetic 2D 
reconstructions. Mammography and MRI can be performed at once or alternate, every 6 months. In the 
case of MRI or contrast material contraindications, ultrasound will be performed instead of MRI. Reporting 
using BI-RADS is recommended. When reaching the age for entering population screening, the individual 
risk profile will be discussed with the woman to opt for the only mammography/DBT screening or for 
continuing the intensive protocol. 
 
Riassunto 
Le donne sottoposte a radioterapia toracica (RTT) in età pediatrica o giovane-adulta, tipicamente per 
linfoma di Hodgkin, hanno un rischio aumentato di sviluppare tumore mammario (TM), in particolare quelle 
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trattate con RTT ad alte dosi. L’incidenza cumulativa di TM tra 40 e 45 anni è del 13-20%, simile a quella 
delle donne BRCA mutate, per le quali è ormai consolidata l’indicazione alla risonanza magnetica (RM) con 
mezzo di contrasto (MdC) annuale. Tuttavia, rispetto agli studi di screening delle donne ad elevato rischio 
eredo-familiare, nelle donne sottoposte a RTT si è osservata una sensibilità relativamente maggiore della 
mammografia e relativamente minore della RM con MdC, correlate alla maggiore incidenza di carcinoma 
duttale in situ con microcalcificazioni e minore neoangiogenesi. Sulla base dell’evidenza disponibile, le 
donne sottoposte a RTT prima dei 30 anni di età con dose cumulativa ≥ 10 Gy dovrebbero essere invitate a 
partire dai 25 anni o almeno da 8 anni dopo la RTT a partecipare a un programma di sorveglianza che 
preveda: 1. colloquio informativo finalizzato all’informazione della donna sul proprio livello di rischio 
correlato alla RTT e ad eventuali altri fattori e sul potenziale delle tecniche di imaging; 2. RM con MdC 
bilaterale annuale con il medesimo protocollo raccomandato per lo screening delle donne ad elevato 
rischio eredo-familiare; 3. mammografia digitale bilaterale annuale o tomosintesi con ricostruzioni 2D 
(proiezioni cranio-caudale e medio-laterale obliqua). Mammografia e RM possono essere eseguite 
contestualmente o alternate a cadenza semestrale. Reperti ed indagini mammografiche e RM saranno 
classificati secondo la scala categoriale BI-RADS. Nel caso di controindicazioni alla RM o alla 
somministrazione di MdC paramagnetico, sarà eseguita ecografia mammaria bilaterale anche in presenza di 
mammografia negativa, contestualmente alla mammografia o con alternanza semestrale. Al 
raggiungimento dell’età per l’invito ai programmi di screening organizzato, il profilo di rischio della donna 
sarà rivalutato e discusso al fine di decidere se optare per l’adesione al protocollo di screening basato su 
mammografia (eventualmente tomosintesi) annuale o biennale o per la prosecuzione dello screening 
intensivo con mammografia e RM annuali. Si raccomanda che il presente protocollo di sorveglianza sia 
effettuato presso centri di radiologia senologica che rispettino i requisiti quali/quantitativi definiti da linee-
guida internazionali e che tutti i dati relativi all’applicazione del protocollo, ivi compresi i cancri d’intervallo, 
siano raccolti mediante database informatizzato al fine di consentire analisi di performance diagnostica e di 
efficacia su scala multicentrica. 
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Background and rationale 
Women who underwent chest radiation therapy (CRT) during pediatric/young-adult age (typically those 
treated for Hodgkin lymphoma) have an increased breast cancer (BC) risk, in particular those who received 
mantle CRT with high doses. However, an increased risk is also associated with RT with moderate doses for 
non-Hodgkin lymphoma, Wilms tumor, leukemia, bone tumors, neuroblastoma or soft tissue sarcoma [1]. 
The cumulative BC incidence from 40 to 45 years of age in women who underwent CRT is 13-20%, higher 
than the incidence observed in the young female general population and similar to that of BRCA mutation 
carriers [1,2]. The age at which CRT was performed and the radiation dose impact on the risk, higher for 
high doses delivered between 10 and 16 years of age. The BC is diagnosed on average about 15 years after 
CRT at about 40 [3], to be compared with a mean age of about 61 in the general female non-exposed 
population [1]. Breast cancers in women who underwent CRT are similar to those we encounter in the 
general female population in regard to histopathologic subtype, receptor status, lymphatic invasion and 
nodal involvement, which play in favor of a potential role of early diagnosis. Conversely, BCs in women who 
underwent CRT exhibit a preferential localization at upper external quadrants more extreme than that 
observed in women with hereditary predisposition (67% versus 48%, respectively). Moreover, in these 
women the possibilities of treatment of BC mostly exclude radiation therapy and chemotherapy with 
doxorubicin [4].  
For women who underwent CRT, international guidelines [2,5,6] recommend annual mammography and 
contrast-enhanced magnetic resonance imaging (MRI), starting from 25 years of age or, for those women 
who had CRT before 30, 8 years after the end of treatment. The rationale is the similar BC incidence in the 
young age for women who had CRT and women with hereditary predisposition associated with relatively 
lower sensitivity of mammography, also related to the need to start at a young age, and higher sensitivity 
of MRI [7].  
The availability and application of guidelines/recommendations for the surveillance of women who 
underwent CRT is relevant for good clinical practice. In fact, BC risk of these women and, as a consequence, 
the importance of breast surveillance is frequently underestimated. In the United States, a study published 
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in 2009 [8] reported that, of 551 women with previous CRT, 47% of those with 25-39 years of age never had 
a mammogram and only 37% had biannual screening mammography, the same percentages being 8% and 
53% between 40 and 50 years of age. Importantly, the screening rate was higher in the presence of a 
specific medical recommendation. The last point highlights the need for clear statements from medical 
bodies. 
Before the MRI introduction, the breast surveillance of women with previous CRT included annual 
physical examination and mammography [9]. This protocol allowed for detecting 60% of BC in the pre-
invasive phase or at T1 stage [10-14]. Two prospective [15,16] and two retrospective studies [17,18] 
compared mammography and MRI. Sensitivity ranged from 67% to70% for mammography, from 63% 
to80% for MRI, with a 92% sensitivity reached only in one retrospective study, with a very small sample size 
for MRI [18]. Importantly, in women who underwent CRT, MRI sensitivity is relatively lower (63-80%) and 
that of mammography is relatively higher (67-70%) than those observed in women with hereditary 
predisposition, due to a higher incidence of ductal carcinoma in situ with microcalcifications [19] and low 
neoangiogenesis. A sensitivity close to 95% can be obtained only using mammography as an adjunct to 
MRI.  
An expert panel [20] recently compared the recommendations proposed by the following working 
groups: North American Children’s Oncology Group (COG), Dutch Childhood Oncology Group (DCOG), 
Scottish Intercollegiate Guidelines Network (SIGN), and UK Children’s Cancer and Leukaemia Group 
(UKCCLG). As a result of this comparison, a series of “harmonized recommendations” were provided: 
physicians, health care providers, and the women who had CRT should be informed on the treatment-
related BC risk (strong recommendation); the surveillance is recommended for doses ≥20 Gy (strong 
recommendation); the surveillance is reasonable for doses between 10 and 19 Gy, taking into account the 
clinical context and further risk factors (moderate recommendation); the surveillance may be reasonable 
for doses between 1 and 9 Gy, taking into account the clinical context and further risk factors (weak 
recommendation); the surveillance implies annual check from 25 years of age or, at least, 8 years after CRT 
up to 50 years of age using mammography, MRI or both of them (strong recommendation); physical 
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examination may be reasonable in countries where only clinical surveillance is available (weak 
recommendation).  
 
Recommendations for breast surveillance of women who underwent CRT 
Considering the available evidence, women who underwent CRT before 30 receiving a cumulative dose ≥ 10 
Gy should be invited after 25 (or, at least, 8 years after CRT) to attend the following program:  
1. dedicated interview about individual risk profile and potential of different breast imaging 
modalities in this specific setting according this document or other recommendations [5,6,21-23];  
2. annual contrast-enhanced MRI using the same protocol recommended for women with hereditary 
predisposition [2, 23]; 
3. annual bilateral 2-view full-field digital mammography or digital breast tomosynthesis (DBT) with 
synthetic 2D reconstructions.  
Mammography and MRI can be performed at once (preferably during only one visit) or alternated , every 6 
months, in relation with local conditions. Reporting using BI-RADS [24] for individual findings and overall is 
recommended. In the case of BI-RADS diagnostic category 1 o 2 after MRI plus mammography, the woman 
will be sent to the next screening event, taking in considerations the lack of evidence in favor of ultrasound 
if both MRI and mammography are negative. In the case of BI-RADS ≥3, the radiologist will evaluate which 
work-up is needed, including additional mammographic views, DBT (if not already performed), ultrasound, 
imaging-guided core or vacuum-assisted needle biopsy. 
When reaching the age for entering population screening program, the individual risk profile will be 
discussed with the woman to opt for the only mammography/DBT screening or for continuing the intensive 
protocol including MRI. 
 We strongly recommend that this surveillance protocol is conducted at breast imaging centers 
respecting quantitative and qualitative requirements defined by international guidelines [2, 25] and that all 
data and results provided by the application of this protocol, including interval cancers, are stored on 
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electronic databases. This will allow for future analyses of diagnostic performance and clinical efficacy on a 
multicenter scale.   
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